ScheBo Biotech

What ScheBo Biotech does

ScheBo Biotech AG is a privately held German biotechnology company founded in 1989 by biochemists and molecular biologists Dr. Ursula Scheefers-Borchel and Dr. Hans Scheefers, headquartered in Gießen, Germany. The company develops, manufactures, and markets in-vitro diagnostic (IVD) products built around proprietary monoclonal antibodies against biomarkers including Pancreatic Elastase 1, Tumor M2-PK (pyruvate kinase), Calprotectin, Lactoferrin, and human hemoglobin. Its core technology stack consists of sandwich ELISA assays for laboratory use, immunochromatographic lateral flow rapid tests for point-of-care settings, and the Master Quick-Prep stool extraction system that unifies pre-analytical sample handling across its ELISA family. Product lines span four medical specialties — Gastroenterology (pancreatic function, IBD), Oncology (M2-PK tumor marker, iFOBT), Veterinary Diagnostics (canine pancreatic elastase), and SARS-CoV-2 Diagnostics (antigen and antibody rapid tests).

The company operates three distribution channels tailored to customer type: direct email/fax catalog sales of ELISA kits to medical laboratories worldwide; point-of-care rapid test kits sold directly to medical practices; and over-the-counter pharmacy sales of the M2-PK and M2-PK+Hb colorectal cancer screening tests through German pharmacies (PZN-listed). Pricing is unit-based with pay-as-you-go billing, and there is no disclosed subscription or licensing model. International reach is delivered through wholly owned regional subsidiaries ScheBo Biotech UK Ltd. (founded 1999) and ScheBo Biotech USA Inc. (founded 2001), alongside research collaborations with universities across Europe, Asia, and the United States.

ScheBo is self-financed and family-influenced, with no external venture or private equity ownership and no public listing. Governance is led by Chairman of the Executive Board Dr. René M. Kröger, Executive Board members Sonja Scheefers and Jeffrey Scheefers, and Supervisory Board Chair Dr. Ursula Scheefers-Borchel. The company holds ISO certification (TÜV Rheinland), AEO-F customs status (since 2011), CE marking for its IVD medical devices, and BfArM listing for SARS-CoV-2 tests. Headcount is reported in the 11–50 employee range, and no revenue, funding, or transaction figures are publicly disclosed.

Name

ScheBo Biotech

Legal name

ScheBo® • Biotech AG

Website

https://schebo.de

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

ScheBo Biotech AG is a German biotechnology company that develops, manufactures, and markets in-vitro diagnostic kits — ELISA tests and rapid point-of-care assays — built around proprietary monoclonal antibodies for gastrointestinal, oncology, and infectious disease testing, sold to laboratories, medical practices, pharmacies, and veterinary clinics across Europe, the UK, and the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Gießen

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. In-vitro Diagnostic Products: Sale of diagnostic test kits and rapid tests for laboratory and point-of-care use. Products include ELISA tests for various biomarkers and immunochromatographic rapid tests.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

ScheBo Biotech AG develops, manufactures, and markets proprietary in-vitro diagnostic (IVD) test kits built on monoclonal antibody technology. Its portfolio includes sandwich ELISA laboratory tests for stool, serum, and plasma biomarkers, lateral flow and immunochromatographic point-of-care rapid tests, and a multifunctional stool sample extraction system, serving gastroenterology, oncology, veterinary diagnostics, and SARS-CoV-2 detection applications.

Product overview

ScheBo Biotech AG is a German biotechnology company specializing in in-vitro diagnostics. The product portfolio spans four medical specialties: Gastroenterology (pancreatic function and inflammatory bowel disease tests), Oncology (tumor marker tests for colorectal cancer and other cancers), Veterinary Diagnostics (canine pancreatic function tests), and SARS-CoV-2 Diagnostics. The product portfolio is organized across three distribution channels: Laboratory tests (ELISA-based tests for professional use), Point-of-Care Rapid Tests (immunochromatographic tests for medical practices), and Pharmacy Tests (consumer-accessible screening tests). Core products include pancreatic elastase tests (stool and serum variants, plus rapid test formats), M2-PK tumor marker tests (plasma, stool, and rapid test formats), Calprotectin and Lactoferrin Smart tests for IBD detection, and Master Quick-Prep sample extraction system. The company develops and manufactures monoclonal antibodies for its diagnostic platforms and operates internationally with subsidiaries in the UK and USA.

Differentiator

Problem solved

Functional benefit

Brands

• ScheBo Quick™: Brand for rapid point-of-care tests including M2-PK Quick, Pancreas Elastase 1 Quick, and SARS-CoV-2 Quick products
• ScheBo Smart™
• ScheBo Master Quick-Prep™
• ScheBo Tumor M2-PK™

Products and services

• ScheBo • Pancreatic Elastase 1™ stool test Sandwich ELISA with two monoclonal antibodies detecting human pancreatic elastase 1 in stool samples; gold standard for non-invasive exocrine pancreatic function testing for clinical laboratories.
• ScheBo • Pancreatic Elastase 1™ serum test Sandwich ELISA for detecting pancreatic elastase 1 in serum samples, used for diagnosis or exclusion of acute pancreatitis; long half-life enables detection of inflammation episodes after several days.
• ScheBo • Tumor M2-PK™ EDTA plasma test Enzyme immunoassay (ELISA) quantifying M2-PK in EDTA plasma for therapy and follow-up monitoring of tumors including renal cell carcinoma, lung carcinoma, and colorectal cancer.
• ScheBo • Tumor M2-PK™ stool test Sandwich ELISA detecting M2-PK enzyme in stool for identification of colorectal polyps and intestinal tumors; independent of occult blood, available at doctor offices and pharmacies.
• ScheBo • M2-PK™ stool test (Pharmacy) Consumer-accessible stool test for early detection of intestinal polyps or colorectal cancer via M2-PK enzyme biomarker; PZN 1005703 available in German pharmacies.
• ScheBo • M2-PK + Hb™ combo stool test (Pharmacy) Combination test for parallel detection of M2-PK enzyme and human hemoglobin in stool; PZN 0242826 available in German pharmacies with laboratory analysis included.
• ScheBo • M2-PK Quick™ Qualitative rapid test for M2-PK detection in stool at medical practices; enables point-of-care colorectal cancer screening with results within minutes.
• ScheBo • 2in1 Quick™ Combination rapid test for parallel detection of M2-PK enzyme and human hemoglobin (Hb) in stool for improved colorectal cancer prevention at medical practices.
• ScheBo • Pancreas Elastase 1 Quick™ Rapid test for detection of pancreatic elastase 1 in stool samples for non-invasive pancreatic function diagnostics at medical practices.
• ScheBo • Elastase 1 Canine ELISA Non-radioactive ELISA test for determination of canine fecal elastase 1 for diagnosis of exocrine pancreatic insufficiency in dogs.
• ScheBo • Pancreas Elastase 1 Quick™ Canine Veterinary rapid test for fecal elastase 1 in dogs when exocrine pancreatic insufficiency is suspected; point-of-care test for immediate diagnosis.
• ScheBo • Calprotectin Smart™ stool test Sandwich ELISA with monoclonal antibodies detecting calprotectin in stool for differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
• ScheBo • Lactoferrin Smart™ stool test Non-invasive quantitative ELISA for early detection and follow-up of inflammatory bowel diseases (IBD); detects lactoferrin as a marker for active intestinal inflammation.
• ScheBo • Hb Smart™ stool test Immunological blood-in-stool test (iFOBT) using specific antibodies against human hemoglobin for colorectal cancer screening.
• ScheBo • Master Quick-Prep™ Multifunctional stool sample extraction system for laboratories, compatible with all ScheBo ELISA products including Pancreatic Elastase 1, Tumor M2-PK, M2-PK+Hb, Hb Smart, Calprotectin Smart, and Lactoferrin Smart tests; average coefficient of variation of 2.7% reported.
• ScheBo • SARS-CoV-2 Quick™ IgM/IgG 2in1 rapid test Immunochromatographic combination test for qualitative detection of SARS-CoV-2 IgM and IgG antibodies in whole blood, serum, or plasma; CE approved medical device.
• ScheBo • SARS-CoV-2 Quick™ Antigen Fluorescence rapid test Immunochromatographic test for qualitative detection of SARS-CoV-2 antigen in swab or serum samples using fluorescence detection; BfArM listed and validated against RT-PCR.
• ScheBo • SARS-CoV-2 Quick™ Antigen Colloidal Gold Method rapid test Immunochromatographic test for qualitative detection of SARS-CoV-2 antigen in swab samples using colloidal gold detection method.
• ScheBo • Brainostic™ GFAP ELISA ELISA test for detection of glial fibrillary acidic protein (GFAP) in laboratory use.
• ScheBo • Brainostic™ Western Blotting Test Western blotting test for glial fibrillary acidic protein (GFAP) detection for laboratory research use.

Quantifiable outcome

• Average coefficient of variation of 2.7% for Master Quick-Prep stool extraction system
• +2 more outcomes

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Universities and University Hospitals (Europe, Asia, United States)coreStrategic or Co-development PartnerScheBo Biotech AG collaborates with various universities and university hospitals in Europe, Asia, and the United States for clinical research and development of diagnostic products. These partnerships support the company's innovation through clinical validation and research collaborations.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• AESKU.Diagnostics GmbH: German diagnostics company developing ELISA and automation systems for autoimmune, infectious disease, and GI biomarkers. Comparable in size and German origin with proprietary IVD assay development and clinical lab focus.
• Biohit Oyj: Finnish diagnostics company developing and marketing GastroPanel and other GI-focused biomarker tests for non-invasive diagnosis of gastric and other GI conditions. Comparable as a European small-cap IVD company specializing in non-invasive GI diagnostics.
• Bühlmann Laboratories AG: Swiss diagnostics company specializing in fecal calprotectin and other IBD/GI biomarkers, including the well-known Bühlmann CALEX Cap sample preparation system and ELISA/automated calprotectin assays. Direct competitor in the stool-based GI diagnostic niche ScheBo targets.
• R-Biopharm AG: German IVD company focused on clinical diagnostics and food analysis, with proprietary ELISA and rapid test development. Comparable in size and German origin, with a similarly diversified IVD portfolio across clinical specialties.
• ALPCO Diagnostics: US-based specialty diagnostics company focused on ELISA kits for diabetes, inflammation, and gastrointestinal research, including calprotectin assays. Comparable niche IVD manufacturer with proprietary assay kits targeting research and clinical labs.
• Immundiagnostik AG: German IVD company headquartered in Bensheim, developing and manufacturing ELISA and clinical chemistry assays with a strong focus on specialty biomarkers including gastrointestinal and inflammatory markers. Highly comparable small/mid-sized German diagnostics specialist with proprietary assay development.

Broad incumbents

• DiaSorin S.p.A. Italian multinational diagnostics company with broad specialty IVD portfolio including GI and oncology markers via Liaison platform. Larger incumbent operating globally with overlapping biomarker menu, but at much greater scale.
• EUROIMMUN Medizinische Labordiagnostika AG: German-based (Lübeck) diagnostics company with extensive autoimmune and infectious disease ELISA/microarray portfolio, now a PerkinElmer subsidiary. Comparable German IVD specialist with proprietary antibody and assay expertise, though much larger scale.

Emerging players

• Calmark Sweden AB: Emerging Swedish diagnostics company developing point-of-care biomarker tests targeting conditions including inflammation. Comparable as a smaller European specialty diagnostics player focused on rapid biomarker testing.

Regional players

• EKF Diagnostics Holdings plc: UK-based diagnostics company with operations in Wales, manufacturing point-of-care and central lab IVD products including HbA1c and specialty biomarkers. Comparable as a European mid-market IVD company with multiple product lines and UK presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/schebo-biotech-ag

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScheBo Biotech